Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)
Status:
Active, not recruiting
Trial end date:
2021-09-08
Target enrollment:
Participant gender:
Summary
Participants will be randomized in a 1:1 ratio to receive Colchicine plus current care per
UCLA treating physicians versus current care per UCLA treating physicians alone (control
arm). Importantly, this adaptive trial design allows for patients in either study arm to
receive other investigational drugs for COVID-19 as new science emerges.